Health Care • Medical/Dental Instruments
$2.69 ▲ +0.08
(+3.07%)
MKT CAP: $113.3M • VOL: 67.4K
52W L $2 52W H $5
APYX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $52.8M | $48.1M | $52.3M |
| YoY Revenue Growth % | +9.9% | -8.1% | — |
| Gross Profit | $33.0M | $29.4M | — |
| Gross Margin % | 62.5% | 61.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.4M | -$18.8M | -$17.3M |
| Operating Margin % | -12.2% | -39.2% | -33.0% |
| Net Income (GAAP) | -$11.2M | -$23.5M | -$18.7M |
| EBITDA (Normalized) | -$5.6M | -$18.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.0M | -$18.0M | -$5.2M |
| Capital Expenditures (CapEx) | $1.1M | $722.0K | — |
| Free Cash Flow (FCF) | -$9.1M | -$18.8M | -$5.2M |
| FCF Margin % | -17.2% | -39.0% | -10.0% |
| Return on Invested Capital (ROIC %) | -28.9% | -45.0% | — |
| Cash & Short-Term Equivalents | $31.7M | $31.7M | — |
| Total Debt (Short + Long Term) | $34.8M | $33.9M | — |
| Total Stockholders' Equity | $14.5M | $14.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR APYX.